CR-CHOP+PD1 inhibitor

Phase 2Small molecule

RRuijin Hospital

CR-CHOP+PD1 inhibitor is one of 7 small molecule programs targeting CHOP. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CHOPRecruiting

CHOPPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in CHOP

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

2 2

Ellence

Pfizer

Phase 3

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Rayos

RRoxane Laboratories

Phase 3

2 5

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 6

Chidamide

CChipscreen Biosciences, Ltd.

Phase 3

1 7

CR-CHOP+PD1 inhibitor

RRuijin Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

CHOP

NCT06701357

Clinical

Trials by Indication[1]

CHOP1 trial

CR-CHOP+X in Previously Untreated DEL

Recruiting·RRuijin Hospital·Phase 2·NCT06701357·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CR-CHOP+PD1 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CR-CHOP+PD1 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CR-CHOP+PD1 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRuijin Hospital

CR-CHOP+PD1 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

CHOP1 trial

References

Drug Info

Quick Facts

Related News